Lab
Labone LLC
Labone LLC was paid $784K by Medicaid between Jan 2018 and Dec 2021, across 88 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 25% of everything it billed.
33Billing provider infoLABONE LLC
COLUMBIA, MO 65201
COLUMBIA, MO 65201
33aNPI1902360019assigned 01/23/2019
33bProvider typeClinical Medical Laboratory
28Total paid$784K
24GClaims73,675
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2021
Compared with peers
Next to other Clinical Medical Laboratory providers in Missouri
Rank by total paid#17 of 61
Median peer was paid$85K
This provider vs. median9.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,857 | $697K | |
| 2019 | 3,571 | $63K | |
| 2020 | 702 | $11K | |
| 2021 | 545 | $13K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 25% | 1,638 | 1,304 | $198K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 2,232 | 1,711 | $96K |
| 80061 | Lipid panel | 5.1% | 3,842 | 3,621 | $40K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5.1% | 560 | 481 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.8% | 6,207 | 4,497 | $37K |
| 80053 | Comprehensive metabolic panel | 4.8% | 4,801 | 3,963 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.8% | 3,858 | 3,620 | $30K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.8% | 995 | 854 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.6% | 1,685 | 1,544 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.6% | 796 | 721 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.6% | 797 | 724 | $20K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.4% | 177 | 170 | $19K |
76 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.4% | 821 | $19K |
| 80164 | 1.8% | 1,173 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.6% | 726 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 1,797 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 1,593 | $9K |
| 84439 | 1.0% | 1,210 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 305 | $8K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 386 | $8K |
| 82607 | <1% | 630 | $8K | |
| 86780 | <1% | 664 | $6K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 233 | $6K |
| 83880 | <1% | 195 | $5K | |
| 87186 | <1% | 660 | $5K | |
| 87077 | <1% | 670 | $5K | |
| 87340 | <1% | 529 | $4K | |
| 84481 | <1% | 333 | $4K | |
| 86762 | <1% | 341 | $4K | |
| 80177 | <1% | 340 | $4K | |
| 86803 | <1% | 334 | $4K | |
| 82746 | <1% | 314 | $4K | |
| 80178 | <1% | 603 | $3K | |
| 80076 | <1% | 600 | $3K | |
| 82140 | <1% | 233 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 82 | $3K |
| 85610 | <1% | 1,050 | $3K | |
| 84153 | <1% | 158 | $3K | |
| 82728 | <1% | 230 | $2K | |
| 86850 | <1% | 327 | $2K | |
| 80156 | <1% | 164 | $2K | |
| 84436 | <1% | 371 | $2K | |
| 82947 | <1% | 590 | $2K | |
| 84146 | <1% | 132 | $2K | |
| 81001 | <1% | 843 | $2K | |
| 87070 | <1% | 332 | $2K | |
| 83540 | <1% | 298 | $2K | |
| 83735 | <1% | 326 | $2K | |
| 83550 | <1% | 223 | $2K | |
| 82570 | <1% | 381 | $2K | |
| 82043 | <1% | 343 | $1K | |
| 86706 | <1% | 152 | $1K | |
| 81003 | <1% | 670 | $1K | |
| 87400 | <1% | 93 | $1K | |
| 80074 | <1% | 28 | $1K | |
| 86704 | <1% | 91 | $934.10 | |
| 86140 | <1% | 195 | $833.66 | |
| 86900 | <1% | 328 | $778.31 | |
| 86901 | <1% | 322 | $766.78 | |
| 86696 | <1% | 49 | $742.68 | |
| 80175 | <1% | 57 | $666.08 | |
| 87075 | <1% | 94 | $604.26 | |
| 85652 | <1% | 248 | $515.00 | |
| 85027 | <1% | 85 | $399.80 | |
| 84702 | <1% | 34 | $373.43 | |
| 87147 | <1% | 79 | $351.55 | |
| 80185 | <1% | 29 | $297.46 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,145 | $295.80 |
| 84134 | <1% | 25 | $288.80 | |
| 84479 | <1% | 60 | $269.63 | |
| 84144 | <1% | 20 | $247.20 | |
| 84550 | <1% | 63 | $217.35 | |
| 80201 | <1% | 15 | $164.78 | |
| 80069 | <1% | 28 | $164.40 | |
| 86038 | <1% | 15 | $161.02 | |
| 82274 | <1% | 12 | $150.10 | |
| 86695 | <1% | 13 | $115.18 | |
| 87081 | <1% | 41 | $101.64 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,093 | $75.12 |
| 82550 | <1% | 13 | $68.73 | |
| 83690 | <1% | 13 | $66.00 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 936 | $60.35 |
| 83655 | <1% | 13 | $59.80 | |
| 82565 | <1% | 12 | $54.66 | |
| 83615 | <1% | 19 | $35.76 | |
| 99082 | 0% | 7,382 | $0.00 | |
| 80050 | General health panel | 0% | 2,046 | $0.00 |
| 36416 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.